Extended Data Fig. 2: ENT1 expression is upregulated by T cells upon activation.
From: Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer
a, Western blot of ENT1 on WT and ENT1-KO JAR cells, representative of n = 2 experiments. b, FACS analysis of ENT1 on WT and ENT1-KO JAR cells with SAHENTA-DY647 following pre-incubation with DMSO or NBMPR. c, Summary analysis of ENT1 MFI values from (b). Mean values ± s.d. from technical triplicates shown. d, FACS analysis of CD8+ T cells activated for 24 hours and then cultured in the presence of NBMPR or DMSO prior to staining with SAHENTA-DY647. Representative of 3 donors. e, Summary analysis from Fig. 1d. Mean values ± s.d. from 3 donors shown. f, FACS analysis of ENT1 expression on CD8+ T cells activated for 72 hours in relation to CD25 expression. Representative of 3 donors. g, FACS analysis of ENT1 and Ki-67 on CD8+ T cell subsets in peripheral blood from healthy donors. Representative of 5 donors. An example gating strategy may be found in Supplementary Fig. 1. h-i, Summary data of percent ENT1+ and ENT1+ Ki-67+ cells, respectively, from each CD8+ T cell subset as shown in (g). Symbols represent each of n = 5 donors (biological replicates). Bars are group mean ± s.d. j, Integrated Genome Viewer (IGV) browser display of the human SLC29A1 gene and promoter region (chr6:44,218,675-44,235,202; GRCh38/hg38) with ChIP-data tracks showing NFAT1 binding in human naive CD4+ T cells either in a resting state or after 5 h anti-CD3/28 activation13. Analysis by two-way ANOVA with Tukey’s multiple comparisons test (c, h-i).
